Bausch Health Companies Inc (BHC)

$6.68 +0.13 (1.98%)
Market Cap 2.47B
Revenue (ttm) 9.63B
Net Income (ttm) -46.00M
EPS (ttm) N/A
PE Ratio 1.74
Forward PE 1.83
Profit Margin -0.48%
Debt to Equity Ratio 147.88
Volume 1,463,000
Avg Vol 2,963,542
Day's Range N/A - N/A
Shares Out 370.35M
Stochastic %K 58%
Beta 0.43
Analysts Hold
Price Target $7.08

Company Profile

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segm...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 514 744 6792
Address:
2150 St. ElzEar Boulevard West, Laval, Canada
highnihilism
highnihilism Oct. 6 at 3:38 AM
$BHC Bausch Health (option volume 10-03-25) 6.68 +2.0% | 612 trades | total $203.3K | 90-day avg $152.8K × 1.33 call $63.2K | put $140.1K | 86% single-leg, 14% multi-leg, 0% contingent
0 · Reply
greyfox
greyfox Oct. 3 at 5:11 PM
$BHC come up everyone. this has to move another 50 cents!
0 · Reply
inflect1on
inflect1on Oct. 3 at 4:24 AM
$BHC despair is at 5.50
0 · Reply
SlowDriver
SlowDriver Oct. 1 at 6:53 PM
$BHC $BLCO are we up today because the government shut down? Does this stop, or delay, the Inflation Reduction Act from moving ahead?
0 · Reply
bnjhnsn
bnjhnsn Oct. 1 at 3:17 PM
$BHC nice movement on low volume. Keep it up!
0 · Reply
Canuck1867
Canuck1867 Sep. 30 at 9:54 PM
$BHC That's my idea for a "buzzer beater" 4pm MOC order of 596,947 $6.45.....
0 · Reply
FU2
FU2 Sep. 30 at 9:10 PM
$BHC gut feeling says hit piece coming out soon with a down grade. Boys need another hard drop. No easier way then a well timed artical. Still long with over 13,000 shares. Not selling, but what a crazy game the markets have become. Criminal
2 · Reply
Canuck1867
Canuck1867 Sep. 30 at 3:44 PM
$BHC We can thank Paulson for not making Trump's list of letter recipients: https://www.pharmtech.com/view/trump-sends-letters-17-leading-pharma-companies-outlining-most-favored-nation-drug-pricing-protocol ....equally not a difficult bet that the CMS process targeting Xifaxin will end up being benign.
0 · Reply
highnihilism
highnihilism Sep. 30 at 9:28 AM
$SKE Skeena Resources: 65 trades, $158K vs $71K avg (2.21x !!). $70K calls / $88K puts. $JKS JinkoSolar: 96 trades, $76K vs $207K avg (0.37x). $69K calls / $7K puts. $BHC Bausch Health: 406 trades, $82K vs $140K avg (0.59x). $69K calls / $13K puts. $SDS ProShares Ultrashort S&P500: 193 trades, $120K vs $269K avg (0.45x). $69K calls / $51K puts.
0 · Reply
Canuck1867
Canuck1867 Sep. 29 at 1:14 PM
$BHC Just leanred that Norwich is the contract Mfg for Xifaxin.... How is it that that has never been mentioned before?? Beyond incredible that they can sue the company and still do business with it. Anyone, Anyone????
1 · Reply
Latest News on BHC
Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV

Sep 30, 2025, 8:00 AM EDT - 5 days ago

Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV

Bausch Health to Announce Third Quarter 2025 Results on October 29

Sep 30, 2025, 7:00 AM EDT - 5 days ago

Bausch Health to Announce Third Quarter 2025 Results on October 29

Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry

Sep 29, 2025, 8:00 AM EDT - 6 days ago

Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry

Bausch Health: Repricing Continues As Deleveraging Gains Traction

Sep 11, 2025, 12:04 PM EDT - 24 days ago

Bausch Health: Repricing Continues As Deleveraging Gains Traction

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

Sep 11, 2025, 8:35 AM EDT - 24 days ago

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

Sep 11, 2025, 7:00 AM EDT - 24 days ago

Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers

Sep 9, 2025, 7:00 AM EDT - 26 days ago

Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers

Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System

Sep 5, 2025, 8:02 AM EDT - 4 weeks ago

Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

Aug 26, 2025, 8:00 AM EDT - 5 weeks ago

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

DRRX

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan

Aug 21, 2025, 8:02 AM EDT - 6 weeks ago

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan

Bausch + Lomb board members resign after Icahn agreement ends

Aug 18, 2025, 5:48 PM EDT - 6 weeks ago

Bausch + Lomb board members resign after Icahn agreement ends

Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes

Aug 15, 2025, 2:30 PM EDT - 7 weeks ago

Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes

Why Bausch Health Stock Surged By Nearly 20%

Aug 12, 2025, 1:02 PM EDT - 7 weeks ago

Why Bausch Health Stock Surged By Nearly 20%

Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners

Aug 7, 2025, 8:00 AM EDT - 2 months ago

Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners

Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 11:30 PM EDT - 2 months ago

Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript

Bausch Health Announces Second Quarter 2025 Results

Jul 30, 2025, 4:05 PM EDT - 2 months ago

Bausch Health Announces Second Quarter 2025 Results

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

Jul 29, 2025, 2:21 PM EDT - 2 months ago

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

DRRX

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

Jul 29, 2025, 7:00 AM EDT - 2 months ago

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

DRRX

Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

Jul 29, 2025, 7:00 AM EDT - 2 months ago

Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand

Jul 28, 2025, 9:10 AM EDT - 2 months ago

Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand

Bausch Health Announces the Appointment of Two New Members to Its Board of Directors

Jul 24, 2025, 8:02 AM EDT - 2 months ago

Bausch Health Announces the Appointment of Two New Members to Its Board of Directors

CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs

Jul 10, 2025, 5:00 PM EDT - 3 months ago

CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs

Bausch Health Appoints New Chief Accounting Officer

Jul 10, 2025, 4:15 PM EDT - 3 months ago

Bausch Health Appoints New Chief Accounting Officer

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs

Jul 9, 2025, 8:00 AM EDT - 3 months ago

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs

Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence

Jul 7, 2025, 8:00 AM EDT - 3 months ago

Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence

Bausch Health to Announce Second Quarter 2025 Results on July 30

Jul 2, 2025, 7:00 AM EDT - 3 months ago

Bausch Health to Announce Second Quarter 2025 Results on July 30

Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility

Jun 26, 2025, 4:30 PM EDT - 3 months ago

Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility

A Billionaire Trump Supporter Is Buying These Two Stocks

Jun 22, 2025, 5:00 AM EDT - 3 months ago

A Billionaire Trump Supporter Is Buying These Two Stocks

PPTA

Bausch Health Shares Rise as Nonexecutive Chairperson Paulson Buys $21.2M in Shares

Jun 18, 2025, 11:01 AM EDT - 3 months ago

Bausch Health Shares Rise as Nonexecutive Chairperson Paulson Buys $21.2M in Shares

Repricing Potential Driven By Deleveraging

Jun 16, 2025, 4:04 AM EDT - 3 months ago

Repricing Potential Driven By Deleveraging

Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States

Jun 4, 2025, 6:59 AM EDT - 4 months ago

Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States

Facial Injectable Market Forecasts Report 2025-2030, Competitive Analysis of Key Players - Allergan, Bausch Health, Bloomage Biotechnology, and Galderma

May 21, 2025, 9:45 AM EDT - 4 months ago

Facial Injectable Market Forecasts Report 2025-2030, Competitive Analysis of Key Players - Allergan, Bausch Health, Bloomage Biotechnology, and Galderma

Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States

May 21, 2025, 6:59 AM EDT - 4 months ago

Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States

Bausch Health Announces 2025 Annual Meeting of Shareholder Results

May 14, 2025, 4:15 PM EDT - 5 months ago

Bausch Health Announces 2025 Annual Meeting of Shareholder Results

Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States

May 14, 2025, 6:59 AM EDT - 5 months ago

Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States

Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens

May 7, 2025, 7:00 AM EDT - 5 months ago

Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens

Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization

May 6, 2025, 8:00 AM EDT - 5 months ago

Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization

Bausch Health Companies Inc. (BHC) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 7:51 PM EDT - 5 months ago

Bausch Health Companies Inc. (BHC) Q1 2025 Earnings Call Transcript

Bausch Health Announces First Quarter 2025 Results

Apr 30, 2025, 4:05 PM EDT - 5 months ago

Bausch Health Announces First Quarter 2025 Results

Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System

Apr 29, 2025, 8:00 AM EDT - 5 months ago

Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System

Bausch Health Learns Icahn Has 34% Economic Interest in Shares

Apr 22, 2025, 9:33 AM EDT - 5 months ago

Bausch Health Learns Icahn Has 34% Economic Interest in Shares

Bausch Health says Carl Icahn has exposure to about 34% of company's shares

Apr 22, 2025, 8:54 AM EDT - 5 months ago

Bausch Health says Carl Icahn has exposure to about 34% of company's shares

Bausch Health Announces Filing of Supplement to Proxy Statement

Apr 22, 2025, 7:25 AM EDT - 5 months ago

Bausch Health Announces Filing of Supplement to Proxy Statement

Bausch + Lomb Reports More Than 100 Million Units of Contacts Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

Apr 21, 2025, 7:00 AM EDT - 5 months ago

Bausch + Lomb Reports More Than 100 Million Units of Contacts Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich

Apr 17, 2025, 3:40 PM EDT - 6 months ago

U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich

Bausch Health Announces Adoption of Shareholder Rights Plan

Apr 14, 2025, 4:30 PM EDT - 6 months ago

Bausch Health Announces Adoption of Shareholder Rights Plan

Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program

Apr 10, 2025, 4:15 PM EDT - 6 months ago

Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program

Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris

Apr 9, 2025, 8:00 AM EDT - 6 months ago

Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris

Bausch Health: Repositioning Aplezin As First Oral Monotherapy For TRD A $3 Billion Opportunity

Apr 5, 2025, 3:00 AM EDT - 6 months ago

Bausch Health: Repositioning Aplezin As First Oral Monotherapy For TRD A $3 Billion Opportunity

Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month

Apr 2, 2025, 8:00 AM EDT - 6 months ago

Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month

highnihilism
highnihilism Oct. 6 at 3:38 AM
$BHC Bausch Health (option volume 10-03-25) 6.68 +2.0% | 612 trades | total $203.3K | 90-day avg $152.8K × 1.33 call $63.2K | put $140.1K | 86% single-leg, 14% multi-leg, 0% contingent
0 · Reply
greyfox
greyfox Oct. 3 at 5:11 PM
$BHC come up everyone. this has to move another 50 cents!
0 · Reply
inflect1on
inflect1on Oct. 3 at 4:24 AM
$BHC despair is at 5.50
0 · Reply
SlowDriver
SlowDriver Oct. 1 at 6:53 PM
$BHC $BLCO are we up today because the government shut down? Does this stop, or delay, the Inflation Reduction Act from moving ahead?
0 · Reply
bnjhnsn
bnjhnsn Oct. 1 at 3:17 PM
$BHC nice movement on low volume. Keep it up!
0 · Reply
Canuck1867
Canuck1867 Sep. 30 at 9:54 PM
$BHC That's my idea for a "buzzer beater" 4pm MOC order of 596,947 $6.45.....
0 · Reply
FU2
FU2 Sep. 30 at 9:10 PM
$BHC gut feeling says hit piece coming out soon with a down grade. Boys need another hard drop. No easier way then a well timed artical. Still long with over 13,000 shares. Not selling, but what a crazy game the markets have become. Criminal
2 · Reply
Canuck1867
Canuck1867 Sep. 30 at 3:44 PM
$BHC We can thank Paulson for not making Trump's list of letter recipients: https://www.pharmtech.com/view/trump-sends-letters-17-leading-pharma-companies-outlining-most-favored-nation-drug-pricing-protocol ....equally not a difficult bet that the CMS process targeting Xifaxin will end up being benign.
0 · Reply
highnihilism
highnihilism Sep. 30 at 9:28 AM
$SKE Skeena Resources: 65 trades, $158K vs $71K avg (2.21x !!). $70K calls / $88K puts. $JKS JinkoSolar: 96 trades, $76K vs $207K avg (0.37x). $69K calls / $7K puts. $BHC Bausch Health: 406 trades, $82K vs $140K avg (0.59x). $69K calls / $13K puts. $SDS ProShares Ultrashort S&P500: 193 trades, $120K vs $269K avg (0.45x). $69K calls / $51K puts.
0 · Reply
Canuck1867
Canuck1867 Sep. 29 at 1:14 PM
$BHC Just leanred that Norwich is the contract Mfg for Xifaxin.... How is it that that has never been mentioned before?? Beyond incredible that they can sue the company and still do business with it. Anyone, Anyone????
1 · Reply
Broview
Broview Sep. 27 at 2:13 AM
$BHC definitely undervalued but headwinds strong?
0 · Reply
badhombre88
badhombre88 Sep. 26 at 7:12 PM
$BHC crossed above 200dma
0 · Reply
FU2
FU2 Sep. 25 at 6:40 PM
$BHC Paulson and groups have total stock price control. All option driven. $6.50 this week. Look at BLCO hard drop to $14.50. Total manipulation of stock price for option money machine. Will it ever change?
1 · Reply
AKTN
AKTN Sep. 25 at 4:07 PM
$BHC so, after Paulson's sloppy 5ths or 6ths or 8ths, this is now below his YUGE position increase he took in August? Bring back Pearson to cap off this shit pile with a bucket of vomit.
0 · Reply
Canuck1867
Canuck1867 Sep. 24 at 3:29 PM
$BHC Just my view but: If you still own this stock and haven't averaged below $7 you really should consider booking a tax loss in here. If you don't want to risk the 30 days be a buyer before the quarter gets reported. Don't hold and agonize - make a move....one way or another.
0 · Reply
Shutupalready12
Shutupalready12 Sep. 24 at 7:32 AM
$BHC what is the timeline for potential fda approvals? Someone here had mentioned they could get approvals sometime in q4 of this year, is that true?
2 · Reply
FU2
FU2 Sep. 23 at 8:41 PM
$BHC so what are we thinking. $6.50 close this week and maybe $6 flat in a couple weeks. Creating new bag holders every week just like clock work. POS
1 · Reply
LeapOptionTrader
LeapOptionTrader Sep. 23 at 12:59 AM
$BHC Take your poison Update on leap :)
0 · Reply
brunoq14
brunoq14 Sep. 22 at 9:17 AM
$BHC New P3 for larsucosterol may create interest.
1 · Reply
truckersam
truckersam Sep. 19 at 8:13 PM
$BHC FRAUDULENT
0 · Reply
truckersam
truckersam Sep. 19 at 6:13 PM
$BHC WHAT'S UP WITH THIS TURD.
0 · Reply
Bobberty
Bobberty Sep. 19 at 1:36 PM
$BHC welp, not liking that bonds are starting to climb again as the American economy looks shaky but I'll take a gamble and get in for 200 shares here. See what the weekend and next weeks/months bring.
1 · Reply